X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15640) 15640
Book Review (1400) 1400
Publication (1178) 1178
Newsletter (113) 113
Magazine Article (48) 48
Newspaper Article (31) 31
Book Chapter (22) 22
Dissertation (14) 14
Transcript (12) 12
Book / eBook (8) 8
Trade Publication Article (8) 8
Conference Proceeding (6) 6
Reference (4) 4
Paper (3) 3
Government Document (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (13934) 13934
humans (10060) 10060
male (7804) 7804
animals (6469) 6469
female (5557) 5557
sulfonamides - administration & dosage (5430) 5430
sulfonamides - pharmacology (5149) 5149
sulfonamides - therapeutic use (4667) 4667
middle aged (3557) 3557
pharmacology & pharmacy (3047) 3047
adult (2996) 2996
rats (2716) 2716
aged (2663) 2663
sulfonamides - adverse effects (2544) 2544
mice (2075) 2075
sulfonamides (2043) 2043
treatment outcome (1960) 1960
celecoxib (1927) 1927
dose-response relationship, drug (1639) 1639
oncology (1500) 1500
abridged index medicus (1456) 1456
sulfonamides - pharmacokinetics (1376) 1376
drug therapy, combination (1336) 1336
administration, oral (1286) 1286
analysis (1268) 1268
time factors (1085) 1085
rats, sprague-dawley (1079) 1079
drug therapy (1077) 1077
research (1018) 1018
cancer (1010) 1010
care and treatment (974) 974
expression (965) 965
double-blind method (954) 954
disease models, animal (906) 906
rosuvastatin calcium (904) 904
sulfonamides - chemistry (889) 889
therapy (820) 820
aged, 80 and over (807) 807
cardiac & cardiovascular systems (804) 804
pyrimidines - administration & dosage (796) 796
rats, wistar (793) 793
pyrimidines - therapeutic use (790) 790
dosage and administration (769) 769
cell line, tumor (764) 764
pharmacokinetics (763) 763
drug administration schedule (762) 762
adolescent (750) 750
medicine & public health (742) 742
biochemistry & molecular biology (739) 739
apoptosis (706) 706
efficacy (701) 701
health aspects (680) 680
neurosciences (664) 664
prospective studies (661) 661
chemistry, medicinal (645) 645
pyrazoles - pharmacology (640) 640
pyrazoles - administration & dosage (632) 632
cyclooxygenase inhibitors - pharmacology (628) 628
medicine, general & internal (627) 627
drug interactions (598) 598
article (591) 591
safety (591) 591
drugs (586) 586
inflammation (570) 570
nonsteroidal antiinflammatory drugs (562) 562
sulfonamides - blood (551) 551
apoptosis - drug effects (548) 548
dogs (542) 542
risk factors (536) 536
cyclooxygenase 2 (534) 534
cells (524) 524
pyrazoles - therapeutic use (524) 524
young adult (522) 522
clinical trials (517) 517
cox-2 inhibitors (515) 515
in-vitro (511) 511
pharmacology (511) 511
pharmacology/toxicology (508) 508
cell biology (503) 503
hypertension (487) 487
ophthalmology (484) 484
drug synergism (483) 483
cyclooxygenase 2 inhibitors (474) 474
medicine, research & experimental (467) 467
hiv infections - drug therapy (462) 462
rosuvastatin (459) 459
pyrimidines - pharmacology (458) 458
pyrazoles (456) 456
activation (455) 455
cyclooxygenase-2 (455) 455
mice, inbred c57bl (455) 455
intraocular pressure - drug effects (454) 454
inhibition (453) 453
physiological aspects (452) 452
immunology (451) 451
internal medicine (449) 449
structure-activity relationship (446) 446
double-blind (444) 444
drug combinations (443) 443
follow-up studies (442) 442
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (14935) 14935
German (262) 262
French (135) 135
Japanese (122) 122
Russian (106) 106
Italian (71) 71
Spanish (57) 57
Chinese (40) 40
Polish (19) 19
Danish (15) 15
Portuguese (15) 15
Romanian (15) 15
Hungarian (13) 13
Czech (12) 12
Dutch (10) 10
Norwegian (9) 9
Swedish (9) 9
Slovak (8) 8
Bulgarian (5) 5
Croatian (5) 5
Turkish (4) 4
Ukrainian (4) 4
Hebrew (2) 2
Korean (2) 2
Serbian (2) 2
Finnish (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastroenterology, ISSN 0016-5085, 2016, Volume 151, Issue 3, pp. 457 - 471.e5
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2015, Volume 21, Issue 16, pp. 3705 - 3715
Purpose: Bruton's tyrosine kinase (BTK) is a critical enzyme in the B-cell receptor pathway and is inhibited by ibrutinib due to covalent binding to the kinase... 
B-CELL RECEPTOR | TUMOR PROLIFERATION | BRUTONS TYROSINE KINASE | CLL | ONCOLOGY | BCL-2 INHIBITOR | INITIAL THERAPY | IN-VIVO | PCI-32765 | KINASE INHIBITOR IBRUTINIB | SINGLE-ARM | Piperazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Apoptosis - drug effects | Humans | Neoplastic Cells, Circulating - metabolism | Male | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Purines - administration & dosage | Bendamustine Hydrochloride - administration & dosage | Protein-Tyrosine Kinases - genetics | Female | bcl-X Protein - biosynthesis | Protein-Tyrosine Kinases - biosynthesis | B-Cell Activating Factor - biosynthesis | Neoplastic Cells, Circulating - drug effects | Pyrimidines - administration & dosage | Gene Expression Regulation, Leukemic - drug effects | Nitrophenols - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - biosynthesis | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Pyrazoles - administration & dosage | B-Cell Activating Factor - genetics | Biphenyl Compounds - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Isoquinolines - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - genetics | Sulfonamides - administration & dosage | Index Medicus
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | Index Medicus | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
The Journal of Bone & Joint Surgery, ISSN 0021-9355, 02/2013, Volume 95, Issue 4, pp. 291 - 296
BACKGROUND:Appropriate pain management affects outcome after hip fracture surgery. Although multimodal pain management is commonly used for pain control for... 
KNEE | SURGERY | DEMENTIA | TOTAL JOINT ARTHROPLASTY | DELIRIUM | HOSPITAL STAY | LOCAL INFILTRATION ANALGESIA | ELDERLY PATIENTS | ORTHOPEDICS | PUMP | CONSUMPTION | POSTOPERATIVE PAIN | Fentanyl - administration & dosage | Single-Blind Method | Hip Fractures - surgery | Pyrazoles - therapeutic use | Prospective Studies | Fentanyl - therapeutic use | Humans | Male | Adrenergic alpha-Agonists - therapeutic use | Arthroplasty, Replacement, Hip - methods | Adrenergic alpha-Agonists - administration & dosage | Epinephrine - therapeutic use | Cyclooxygenase 2 Inhibitors - therapeutic use | Statistics, Nonparametric | Aged, 80 and over | Anesthetics, Local - therapeutic use | Anesthetics, Local - administration & dosage | Oxycodone - therapeutic use | Oxycodone - administration & dosage | Cyclooxygenase 2 Inhibitors - administration & dosage | Pain Management - methods | Analgesics, Opioid - therapeutic use | Anti-Bacterial Agents - administration & dosage | Morphine - administration & dosage | Sulfonamides - administration & dosage | Ketorolac - therapeutic use | Pain, Postoperative - drug therapy | Epinephrine - administration & dosage | Patient Satisfaction | Anti-Bacterial Agents - therapeutic use | Cefmetazole - therapeutic use | Female | Drug Therapy, Combination | Analgesia, Patient-Controlled | Treatment Outcome | Amides - therapeutic use | Celecoxib | Chi-Square Distribution | Pyrazoles - administration & dosage | Sulfonamides - therapeutic use | Analgesics, Opioid - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Injections, Intra-Articular | Aged | Ketorolac - administration & dosage | Pain Measurement | Amides - administration & dosage | Morphine - therapeutic use | Cefmetazole - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2017, Volume 66, Issue 6, pp. 1138 - 1148
Graphical abstract 
Gastroenterology and Hepatology | Antiviral agents | Ombitasvir | Ritonavir | Ledipasvir | Real-world | Genotype 1 | Paritaprevir | Sustained virologic response | Hepatitis C, Chronic | Sofosbuvir | Dasabuvir | Randomized controlled trials | PLUS RIBAVIRIN | VIRUS-INFECTION | CHRONIC HEPATITIS-C | SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | Chronic | HEPATOCELLULAR-CARCINOMA | TREATMENT-EXPERIENCED PATIENTS | Hepatitis C | GASTROENTEROLOGY & HEPATOLOGY | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepatitis C, Chronic - physiopathology | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Carbamates - administration & dosage | Neoplasm Recurrence, Local - etiology | Liver Neoplasms - etiology | Young Adult | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Carcinoma, Hepatocellular - etiology | Retrospective Studies | Drug Therapy, Combination | Glomerular Filtration Rate | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Spain | Anilides - administration & dosage | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Sulfonamides - administration & dosage | Cohort Studies | Uracil - analogs & derivatives | Genetic aspects | Safety and security measures | Hepatitis C virus | Clinical trials | Chronic infection | Data processing | Hepatocellular carcinoma | Multivariate analysis | Patients | Clinical outcomes | Ribavirin | Genotype & phenotype | Cohort analysis | Fibrosis | Safety | Drug therapy | Antiviral drugs | Genotypes | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9941, pp. 403 - 413
Journal Article
Gut, ISSN 0017-5749, 09/2016, Volume 65, Issue 9, pp. 1439 - 1446
ObjectiveThe objective of this study was to assess the efficacy, safety and tolerability of vonoprazan, a novel potassium-competitive acid blocker, as a... 
antibiotic therapy | clinical trials | Helicobacter pylori infection | helicobacter pylori - treatment | CLARITHROMYCIN | LANSOPRAZOLE | MULTICENTER | MANAGEMENT | CLINICAL-TRIAL | PHARMACOKINETICS | JAPAN | INFECTION | MONOFUMARATE TAK-438 | GASTROENTEROLOGY & HEPATOLOGY | AMOXICILLIN | Humans | Middle Aged | Helicobacter Infections - complications | Helicobacter pylori - drug effects | Male | Drug Monitoring - methods | Proton Pump Inhibitors - administration & dosage | Pyrroles - administration & dosage | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Metronidazole - adverse effects | Peptic Ulcer - diagnosis | Pyrroles - adverse effects | Adult | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Helicobacter Infections - diagnosis | Lansoprazole - administration & dosage | Proton Pump Inhibitors - adverse effects | Double-Blind Method | Drug Administration Schedule | Clarithromycin - adverse effects | Metronidazole - administration & dosage | Treatment Outcome | Drug Therapy, Combination - methods | Lansoprazole - adverse effects | Sulfonamides - adverse effects | Amoxicillin - adverse effects | Helicobacter pylori - isolation & purification | Anti-Bacterial Agents - administration & dosage | Peptic Ulcer - drug therapy | Breath Tests - methods | Peptic Ulcer - etiology | Sulfonamides - administration & dosage | Usage | Safety and security measures | Research | Helicobacter pylori | Antacids | Index Medicus | Abridged Index Medicus | Helicobacter Pylori | HELICOBACTER PYLORI - TREATMENT | CLINICAL TRIALS | 1506 | ANTIBIOTIC THERAPY | HELICOBACTER PYLORI INFECTION
Journal Article
JAMA, ISSN 0098-7484, 03/2015, Volume 313, Issue 12, pp. 1223 - 1231
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 05/2010, Volume 55, Issue 18, pp. 1915 - 1922
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9941, pp. 414 - 426
Journal Article